Calix (CALX) Form 4 CALIX / John Matthew Collins ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Collins John Matthew

(Last) (First) (Middle)

C/O CALIX, INC.

2777 ORCHARD PARKWAY

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CALIX, INC [ (CALX) ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Commercial Ops Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.26	01/31/2025		A		107,775		02/08/2025(1)	02/08/2034	Common Stock	107,775	$0	107,775	D
Stock Option (right to buy)	$34.26	01/31/2025		A		68,850		02/08/2025(2)	02/08/2034	Common Stock	68,850	$0	68,850	D
Stock Option (right to buy)	$39.68	01/31/2025		A		195,000		01/31/2026(3)	01/31/2035	Common Stock	195,000	$0	195,000	D

Explanation of Responses:

1. On February 8, 2024, the reporting person was granted a performance-based stock option to purchase 225,000 shares of common stock. On January 31, 2025, the Talent and Compensation Committee (the Committee) of the Board of Directors of Calix, Inc. (Calix) determined that the performance criteria governing 47.9% of the grant had been achieved, resulting in 107,775 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.

2. On February 8, 2024, the reporting person was granted a performance-based option to purchase 75,000 shares of common stock. On January 31, 2025, the Committee determined that the performance criteria governing 91.8% of the grant had been achieved, resulting in 68,850 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.

3. The option vests: (i) as to 25% of the shares of common stock subject to the option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

Remarks:

	/s/ Tom Gemetti as Attorney-in-Fact for John Matthew Collins	02/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.